Genmab Meets Conditions For $97/shr Merus Tender Offer

Genmab’s subsidiary has met the conditions for its $97-per-share tender offer to acquire Merus after 71,463,077 shares (94.2% of outstanding) were tendered by the Dec. 11 deadline; a 10-business-day subsequent offering period runs Dec. 12–29 to buy more shares at the same price, after which Genmab will pursue follow-on steps to acquire remaining stock. The acquisition supports Genmab’s move to a fully owned model and bolsters its oncology pipeline with Merus’s lead asset petosemtamab, which Genmab plans to launch in 2027 and projects to have at least $1 billion in annual sales potential by 2029. Genmab’s stock reacted positively, closing Dec. 12 at $32.30 (+3.39%) and trading up to $33.30 (+3.10%) in overnight trade.

Analysis

Genmab's subsidiary Genmab Holding II B.V. announced that the conditions for its $97-per-share cash tender offer for Merus have been met after 71,463,077 shares, or 94.2% of outstanding stock, were tendered by the Dec. 11 deadline; a subsequent 10-business-day offering period runs Dec. 12–29 during which Genmab will buy additional shares at the same price, followed by disclosed follow-on steps to acquire remaining shares. The transaction is presented as a strategic shift toward a fully owned model and immediately adds Merus's lead asset, petosemtamab, to Genmab's pipeline with an internal launch target of 2027 and projected at least $1 billion in annual sales by 2029. Market reaction to the announcement was modestly positive: Genmab shares closed Dec. 12 at $32.30 (+3.39%) and traded up to $33.30 in overnight trade, reflecting investor approval of the deal logic but not providing information on financing or integration costs. Key near-term drivers remain the subsequent offering period outcomes, the mechanics and timing of follow-on acquisition steps, and execution risk around the 2027 launch and commercialization assumptions underpinning the $1 billion sales projection.

Key Decisions for Investors

• Merus holders seeking certainty should accept the $97 cash offer in the subsequent offering period given 94.2% already tendered, while holders seeking maximum upside can wait but should expect follow-on steps to complete the deal
• Genmab investors should monitor disclosures on how the acquisition will be financed and any guidance on integration costs because those details will materially affect near-term balance sheet and EPS dynamics
• Track development and regulatory milestones for petosemtamab toward the 2027 launch and the assumptions behind the $1 billion-by-2029 projection, and base position increases on confirmed clinical and commercial progress
• Given the modest positive stock reaction, consider taking partial profits or implementing hedges ahead of final close and integration updates to limit exposure to execution risk